miR-34a as hub of T cell regulation networks

Abstract

Background Micro(mi)RNAs are increasingly recognized as central regulators of immune cell function. While it has been predicted that miRNAs have multiple targets, the majority of these predictions still await experimental confirmation. Here, miR-34a, a well-known tumor suppressor, is analyzed for targeting genes involved in immune system processes of leucocytes. Methods Using an in-silico approach, we combined miRNA target prediction with GeneTrail2, a web tool for Multi-omics enrichment analysis, to identify miR-34a target genes, which are involved in the immune system process subcategory of Gene Ontology. Results Out of the 193 predicted target genes in this subcategory we experimentally tested 22 target genes and confirmed binding of miR-34a to 14 target genes including VAMP2 , IKBKE , MYH9 , MARCH8 , KLRK1 , CD11A , TRAFD1 , CCR1 , PYDC1 , PRF1 , PIK3R2 , PIK3CD , AP1B1 , and ADAM10 by dual luciferase assays. By transfecting Jurkat, primary CD4 + and CD8 + T cells with miR-34a, we demonstrated that ectopic expression of miR-34a leads to reduced levels of endogenous VAMP2 and CD11A, which are central to the analyzed subcategories. Functional downstream analysis of miR-34a over-expression in activated CD8 + T cells exhibits a distinct decrease of PRF1 secretion. Conclusions By simultaneous targeting of 14 mRNAs miR-34a acts as major hub of T cell regulatory networks suggesting to utilize miR-34a as target of intervention towards a modulation of the immune responsiveness of T-cells in a broad tumor context. Electronic supplementary material The online version of this article (10.1186/s40425-019-0670-5) contains supplementary material, which is available to authorized users.

Severe COVID-19: NLRP3 Inflammasome Dysregulated

“…In search for a pathway to relate sustained NLRP3 inflammasome activation in aging we found a microRNA that has Pyrin-only protein 1 (POP1) as its target ( 33 ). This miR-34-5p is found to be increased in skeletal muscle and in serum-derived extracellular vesicles in an experimental model and considered as an “inflammiR” ( 34 ).…”

Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia

“…However, other in vitro experiments showed that miR-34a restoration can induce cell-cycle arrest and apoptosis [211]. In addition, miR-34a targets NOTCH1, E2F1 and B-MYB, which promote CLL cell proliferation [212], regulates the NF-κβ signaling in T-cells [213] and has a key role in the immune system response in cancer [214]. Thus therapeutic strategy involving the administration of miR-34a mimics in CLL may warrant further studies.…”

Down-regulation of tumor suppressor miR-34a contributes to head and neck cancer by up-regulating MET oncogene and modulating tumor immune evasion

“…Treatment with a miR-34a inhibitor attenuates p53-mediated apoptosis in response to genotoxic stress, whereas the ectopic expression of miR-34a causes a signi cant reprogramming of gene expression and induces apoptosis and cell cycle arrest (23). miR-34a has been shown to directly target the 3′ UTRs of numerous mRNAs with roles in oncogenesis beyond p53, including Bcl-2, PIK3R2, c-Myc, SIRT1, VAMP2, IKBKE, MYH9, KLRK1, CD11A, SDK4-6, Notch1, TRAFD1, and CCR1 (23)(24)(25)(26)(27), which may contribute to its tumor-suppressive function.…”